Search

Your search keyword '"Hero, B."' showing total 165 results

Search Constraints

Start Over You searched for: Author "Hero, B." Remove constraint Author: "Hero, B." Topic neuroblastoma Remove constraint Topic: neuroblastoma
165 results on '"Hero, B."'

Search Results

1. Reproducibility Analysis of Radiomic Features on T2-weighted MR Images after Processing and Segmentation Alterations in Neuroblastoma Tumors.

2. Image-defined risk factors in localized thoracic neuroblastoma and ganglioneuroma.

3. Genomic ALK alterations in primary and relapsed neuroblastoma.

4. Neuroblastoma arises in early fetal development and its evolutionary duration predicts outcome.

5. Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting.

6. Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry.

7. Adrenocortical Tumors and Pheochromocytoma/Paraganglioma Initially Mistaken as Neuroblastoma-Experiences From the GPOH-MET Registry.

8. Durchführung und Befundung der 123I-mIBG-Szintigraphie bei Kindern und Jugendlichen mit Neuroblastom (Version 3) – DGN-Handlungsempfehlung (S1-Leitlinie), Stand: 2/2020 – AWMF-Registernummer: 031-040.

9. Diagnosis and Management of Opsoclonus-Myoclonus-Ataxia Syndrome in Children: An International Perspective.

10. Hypercalcemia is a frequent side effect of 13-cis-retinoic acid treatment in patients with high-risk neuroblastoma.

11. Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification.

12. Long-term follow-up of children with neuroblastoma receiving radiotherapy to metastatic lesions within the German Neuroblastoma Trials NB97 and NB 2004.

13. Neuroblastoma Screening at 1 Year of Age: The Final Results of a Controlled Trial.

14. Neuroblastoma.

15. NK Cell-mediated Neuroblastoma Cell Lysis is Enhanced by IgG From Patients With Pediatric Opsoclonus-Myoclonus Syndrome.

16. The prognostic strength of serum LDH and serum ferritin in children with neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.

17. PRIMAGE project: predictive in silico multiscale analytics to support childhood cancer personalised evaluation empowered by imaging biomarkers.

18. Extended induction chemotherapy does not improve the outcome for high-risk neuroblastoma patients: results of the randomized open-label GPOH trial NB2004-HR.

19. Biochemical testing for neuroblastoma using plasma free 3-O-methyldopa, 3-methoxytyramine, and normetanephrine.

20. A new risk score for patients after first recurrence of stage 4 neuroblastoma aged ≥18 months at first diagnosis.

21. A mechanistic classification of clinical phenotypes in neuroblastoma.

22. LDHA in Neuroblastoma Is Associated with Poor Outcome and Its Depletion Decreases Neuroblastoma Growth Independent of Aerobic Glycolysis.

23. Genomic Amplifications and Distal 6q Loss: Novel Markers for Poor Survival in High-risk Neuroblastoma Patients.

24. Long-term outcomes of the GPOH NB97 trial for children with high-risk neuroblastoma comparing high-dose chemotherapy with autologous stem cell transplantation and oral chemotherapy as consolidation.

25. Retrospective analysis of relapsed abdominal high-risk neuroblastoma.

26. Genomic Profiles of Neuroblastoma Associated With Opsoclonus Myoclonus Syndrome.

27. Molecular Classification Substitutes for the Prognostic Variables Stage, Age, and MYCN Status in Neuroblastoma Risk Assessment.

29. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.

30. 2017 GPOH Guidelines for Diagnosis and Treatment of Patients with Neuroblastic Tumors.

31. Neuroblastoma survivors are at increased risk for second malignancies: A report from the International Neuroblastoma Risk Group Project.

32. Liver transplantation as a potentially lifesaving measure in neuroblastoma stage 4S.

33. Lack of immunocytological GD2 expression on neuroblastoma cells in bone marrow at diagnosis, during treatment, and at recurrence.

34. MYCN and HDAC5 transcriptionally repress CD9 to trigger invasion and metastasis in neuroblastoma.

35. Correction factors for self-selection when evaluating screening programmes.

36. Neuroblastoma messenger RNA is frequently detected in bone marrow at diagnosis of localised neuroblastoma patients.

37. Transcription factor activating protein 2 beta (TFAP2B) mediates noradrenergic neuronal differentiation in neuroblastoma.

38. Telomerase activation by genomic rearrangements in high-risk neuroblastoma.

39. Minimal residual disease detection in autologous stem cell grafts from patients with high risk neuroblastoma.

40. Mutational dynamics between primary and relapse neuroblastomas.

41. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.

42. Revised risk estimation and treatment stratification of low- and intermediate-risk neuroblastoma patients by integrating clinical and molecular prognostic markers.

43. MIBG scans in patients with stage 4 neuroblastoma reveal two metastatic patterns, one is associated with MYCN amplification and in MYCN-amplified tumours correlates with a better prognosis.

44. FOXP1 inhibits cell growth and attenuates tumorigenicity of neuroblastoma.

45. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.

46. Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma.

47. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.

48. Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) predicts outcome in patients with stage 4 disease: A study from the International Neuroblastoma Risk Group Database.

49. Hox-C9 activates the intrinsic pathway of apoptosis and is associated with spontaneous regression in neuroblastoma.

50. Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study.

Catalog

Books, media, physical & digital resources